-$0.22 EPS Expected for Viewray Inc (VRAY) This Quarter
Wall Street analysts expect Viewray Inc (NASDAQ:VRAY) to report earnings per share (EPS) of ($0.22) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Viewray’s earnings. The lowest EPS estimate is ($0.23) and the highest is ($0.21). Viewray reported earnings of ($0.26) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 15.4%. The business is scheduled to report its next earnings report on Monday, November 12th.
On average, analysts expect that Viewray will report full-year earnings of ($0.76) per share for the current financial year, with EPS estimates ranging from ($0.81) to ($0.70). For the next fiscal year, analysts expect that the business will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.67) to ($0.44). Zacks’ EPS averages are an average based on a survey of analysts that cover Viewray.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings results on Friday, August 3rd. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.09). Viewray had a negative net margin of 83.84% and a negative return on equity of 353.05%. The business had revenue of $16.44 million during the quarter, compared to analysts’ expectations of $15.97 million. During the same period in the prior year, the business earned ($0.15) EPS. The business’s quarterly revenue was up 2255.3% on a year-over-year basis.
Shares of VRAY stock opened at $9.87 on Wednesday. The company has a current ratio of 3.33, a quick ratio of 2.64 and a debt-to-equity ratio of 1.17. Viewray has a 52 week low of $5.11 and a 52 week high of $13.21.
In other news, insider Fmr Llc sold 295,850 shares of Viewray stock in a transaction on Thursday, July 26th. The shares were sold at an average price of $12.08, for a total transaction of $3,573,868.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Orbimed Advisors Llc sold 185,948 shares of Viewray stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $9.95, for a total transaction of $1,850,182.60. The disclosure for this sale can be found here. Insiders sold a total of 3,436,496 shares of company stock valued at $36,326,958 in the last three months. 43.93% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in VRAY. Fosun International Ltd lifted its position in shares of Viewray by 61.2% during the 1st quarter. Fosun International Ltd now owns 10,767,975 shares of the company’s stock worth $69,239,000 after purchasing an additional 4,090,000 shares during the last quarter. FMR LLC lifted its position in shares of Viewray by 36.9% during the 2nd quarter. FMR LLC now owns 7,670,767 shares of the company’s stock worth $53,082,000 after purchasing an additional 2,069,086 shares during the last quarter. BlackRock Inc. lifted its position in shares of Viewray by 59.3% during the 2nd quarter. BlackRock Inc. now owns 2,962,937 shares of the company’s stock worth $20,503,000 after purchasing an additional 1,102,991 shares during the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of Viewray during the 2nd quarter worth $6,852,000. Finally, Park West Asset Management LLC lifted its position in shares of Viewray by 31.8% during the 1st quarter. Park West Asset Management LLC now owns 3,446,113 shares of the company’s stock worth $22,158,000 after purchasing an additional 830,898 shares during the last quarter. 91.95% of the stock is owned by institutional investors and hedge funds.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Further Reading: New Google Finance Tool and Screening Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.